AbbVie

It's unclear whether tariffs will influence more companies to make more drugs in the U.S. like President Donald Trump is hoping for, some experts said.

Fremanezumab shows safety, efficacy in phase III trial of pediatric patients

American stocks have crashed this year, and are continuing to lag behind their global peers in countries like Germany, France, and China. This performance may continue next week when Trump implements his Liberation Day tariffs, triggering a trade war. Investing in quality blue-chip ETFs can be a good way to prepare for these tariffs. This […]

/PRNewswire-PRWeb/ -- Women We Admire is pleased to announce The Rising Star Women Leaders in Medicine for 2025. Medicine is a constantly evolving field that...

Half of patients who used delgocitinib cream for chronic hand eczema had a profound response, and a third who stopped treatment stayed clear or nearly clear for 8 weeks.

For both induction and maintenance therapy, subcutaneous guselkumab significantly improves clinical outcomes in patients with ulcerative colitis as well as in those with Crohn's disease.

Oz said that he will sell off parts of his significant and diverse investment portfolio

Bleeding should prompt more investigations for malignancy, researchers suggest

Biologic went head to head against ustekinumab in SEQUENCE trial

Such infections include those caused by Gram-negative bacteria

Dazukibart targets specific molecular pathology of chronic systemic autoimmune disease

North American venture funding spiked in the final quarter of 2024, closing out an up year for startup investment driven by continued momentum around artificial intelligence.

However, imlunestrant failed to improve PFS among entire trial population

Cytokine release syndrome developed in all patients, including grade 3/4 events in nearly half

More Americans are living with pain now, CDC data show

Meta-analysis shows better PFS, OS with RT-first approach, but issue requires more study

Patients with GPA completely weaned off glucocorticoids were four times as likely to flare compared with those kept on a low dose, though these flares were minor.

A major reason for the increase in prevalence is increased survival from improved management

News and commentary from the psychiatry world

A study of ruxolitinib cream in patients with lichen planus indicated that the topical JAK inhibitor is a promising potential treatment for cutaneous lichen planus that is also well tolerated.